FindTrial
Sign In

13-cis retinoic acid as continuation therapy in children with advanced neuroblastoma in complete or good partial remission

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN17384971
Enrollment
Unknown
Registered
2001-07-01
Start date
1995-03-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumour of childhood Cancer Neuroblastoma

Interventions

Initial therapy followed by either: 1. Continuation Therapy: Thirteen-cis-retinoic acid 2. Control: Placebo

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Stage III or IV neuroblastoma 2. In complete or good partial remission following initial therapy

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026